2-amino-5-phosphonovalerate has been researched along with Huntington Disease in 5 studies
2-Amino-5-phosphonovalerate: The D-enantiomer is a potent and specific antagonist of NMDA glutamate receptors (RECEPTORS, N-METHYL-D-ASPARTATE). The L form is inactive at NMDA receptors but may affect the AP4 (2-amino-4-phosphonobutyrate; APB) excitatory amino acid receptors.
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Complexin II is reduced in Huntington's disease (HD) patients and in the R6/2 mouse model of HD." | 1.33 | A similar impairment in CA3 mossy fibre LTP in the R6/2 mouse model of Huntington's disease and in the complexin II knockout mouse. ( Brose, N; Gibson, HE; Jones, S; Morton, AJ; Reim, K, 2005) |
| " Morphological criteria were used to determine the toxic effects of glutamate in 6-, 12-, and 18-day-old cultures which were examined before and after 1-3 h of exposure to glutamate." | 1.28 | Characterization and mechanism of glutamate neurotoxicity in primary striatal cultures. ( Beal, MF; DiFiglia, M; Freese, A; Koroshetz, WJ; Martin, JB, 1990) |
| "Quinolinic acid (QA) is an endogenous excitotoxin present in mammalian brain that reproduces many of the histologic and neurochemical features of Huntington's disease (HD)." | 1.27 | Systemic approaches to modifying quinolinic acid striatal lesions in rats. ( Beal, MF; Ferrante, RJ; Kowall, NW; Martin, JB; Swartz, KJ, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gibson, HE | 1 |
| Reim, K | 1 |
| Brose, N | 1 |
| Morton, AJ | 1 |
| Jones, S | 1 |
| Olney, JW | 1 |
| Zorumski, CF | 1 |
| Stewart, GR | 1 |
| Price, MT | 1 |
| Wang, GJ | 1 |
| Labruyere, J | 1 |
| Freese, A | 1 |
| DiFiglia, M | 1 |
| Koroshetz, WJ | 1 |
| Beal, MF | 2 |
| Martin, JB | 2 |
| Kowall, NW | 1 |
| Swartz, KJ | 1 |
| Ferrante, RJ | 1 |
| Mazzocchi-Jones, D | 1 |
| Döbrössy, M | 1 |
| Dunnett, SB | 1 |
5 other studies available for 2-amino-5-phosphonovalerate and Huntington Disease
| Article | Year |
|---|---|
A similar impairment in CA3 mossy fibre LTP in the R6/2 mouse model of Huntington's disease and in the complexin II knockout mouse.
Topics: 2-Amino-5-phosphonovalerate; Adaptor Proteins, Vesicular Transport; Age Factors; Animals; Anticonvul | 2005 |
Excitotoxicity of L-dopa and 6-OH-dopa: implications for Parkinson's and Huntington's diseases.
Topics: 2-Amino-5-phosphonovalerate; 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Chick Embryo; Dibenzocyc | 1990 |
Characterization and mechanism of glutamate neurotoxicity in primary striatal cultures.
Topics: 2-Amino-5-phosphonovalerate; Animals; Calcium; Cells, Cultured; Corpus Striatum; Glutamates; Glutami | 1990 |
Systemic approaches to modifying quinolinic acid striatal lesions in rats.
Topics: 2-Amino-5-phosphonovalerate; Allopurinol; Amino Acids; Animals; Antioxidants; Baclofen; Corpus Stria | 1988 |
Embryonic striatal grafts restore bi-directional synaptic plasticity in a rodent model of Huntington's disease.
Topics: Animals; Biophysics; Chi-Square Distribution; Corpus Striatum; Disease Models, Animal; Electric Stim | 2009 |